全文获取类型
收费全文 | 15107篇 |
免费 | 771篇 |
国内免费 | 28篇 |
专业分类
耳鼻咽喉 | 146篇 |
儿科学 | 483篇 |
妇产科学 | 404篇 |
基础医学 | 1995篇 |
口腔科学 | 162篇 |
临床医学 | 1777篇 |
内科学 | 2788篇 |
皮肤病学 | 258篇 |
神经病学 | 1590篇 |
特种医学 | 386篇 |
外国民族医学 | 4篇 |
外科学 | 1566篇 |
综合类 | 110篇 |
一般理论 | 9篇 |
预防医学 | 1797篇 |
眼科学 | 219篇 |
药学 | 988篇 |
1篇 | |
中国医学 | 8篇 |
肿瘤学 | 1215篇 |
出版年
2024年 | 111篇 |
2023年 | 220篇 |
2022年 | 357篇 |
2021年 | 675篇 |
2020年 | 387篇 |
2019年 | 667篇 |
2018年 | 678篇 |
2017年 | 480篇 |
2016年 | 521篇 |
2015年 | 558篇 |
2014年 | 786篇 |
2013年 | 887篇 |
2012年 | 1344篇 |
2011年 | 1280篇 |
2010年 | 681篇 |
2009年 | 568篇 |
2008年 | 915篇 |
2007年 | 886篇 |
2006年 | 808篇 |
2005年 | 739篇 |
2004年 | 715篇 |
2003年 | 534篇 |
2002年 | 456篇 |
2001年 | 54篇 |
2000年 | 50篇 |
1999年 | 51篇 |
1998年 | 99篇 |
1997年 | 71篇 |
1996年 | 62篇 |
1995年 | 44篇 |
1994年 | 38篇 |
1993年 | 35篇 |
1992年 | 18篇 |
1991年 | 14篇 |
1990年 | 6篇 |
1989年 | 11篇 |
1988年 | 14篇 |
1987年 | 7篇 |
1986年 | 8篇 |
1985年 | 6篇 |
1984年 | 7篇 |
1983年 | 7篇 |
1982年 | 7篇 |
1981年 | 6篇 |
1980年 | 7篇 |
1978年 | 5篇 |
1977年 | 2篇 |
1976年 | 10篇 |
1973年 | 2篇 |
1972年 | 2篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
51.
Elliot G. Arsoniadis Yunhua Fan Stephanie Jarosek Wolfgang B. Gaertner Genevieve B. Melton Robert D. Madoff Mary R. Kwaan 《Annals of surgical oncology》2018,25(3):720-728
Background
Improved multimodality rectal cancer treatment has increased the use of sphincter-preserving surgery. This study sought to determine whether African American (AA) patients with rectal cancer receive sphincter-preserving surgery at the same rate as non-AA patients.Methods
The study used the Nationwide Inpatient Sample for years 1998–2012 to compare AA and non-AA patients with rectal cancer undergoing low anterior resection or abdominoperineal resection. The logistic regression model was used to adjust for age, gender, admission type, Elixhauser comorbidity index, and hospital factors such as size, location (urban vs.rural), teaching status, and procedure volume.Results
The search identified 22,697 patients, 1600 of whom were identified as AA. After adjustment for age and gender, the analysis showed that AA patients were less likely to undergo sphincter-preserving surgery than non-AA patients [odds ratio (OR) 0.70; 95% confidence interval (CI) 0.63–0.78; p < 0.0001). After further adjustment for the Elixhauser comorbidity index, admission type, hospital-specific factors, and insurance status, the analysis showed that AA patients still were less likely to undergo sphincter-preserving surgery (OR 0.78; 95% CI 0.70–0.87; p < 0.0001). Although the proportion of non-AA patients undergoing sphincter-preserving surgery increased during the study period (p = 0.0003), this trend was not significant for the AA patients (p = 0.13).Conclusion
In this data analysis, the AA patients with rectal cancer had lower rates of sphincter-preserving surgery than the non-AA patients, even after adjustment for patient- and hospital-specific factors. Further work is required to elucidate why. Eliminating racial disparities in rectal cancer treatment should continue to be a priority for the surgical community.52.
53.
Stephanie Bee Ming Tan Justin Greenslade David Martin Michael Talbot Ken Loi George Hopkins 《Surgery for obesity and related diseases》2018,14(3):271-275
Background
Worldwide, the laparoscopic sleeve gastrectomy (LSG) is becoming the dominant bariatric procedure due to its reliable weight loss and low complication rate. Portomesenteric vein thrombosis (PVT) is an uncommon complication of LSG with an incidence of .3% to 1% and can lead to serious consequences, such as bowel ischemia and death.Objectives
This paper will present the presentation, risk factors, treatment, and long-term outcomes of patients who had PVT post-LSG.Setting
Five bariatric centers in a private setting in Australia.Methods
Retrospective data were collected from 5 bariatric centers across Australia from 2007 to 2016.Results
Across 5 centers, 5951 patients underwent LSG; 18 had recognized PVT (.3%). The mean body mass index was 41.8. Of patients, 39% had a history or family history of deep vein thrombosis. The average time to diagnosis was 13 days (range, 5–25). Treatment was nonoperative with anticoagulation in 94%. One patient required operative management with bowel resection. All patients were discharged on therapeutic anticoagulation. Mean total weight loss was 27.7% (14.8%–66.3%). Mean follow-up was 10 months. There were no mortalities. Given the low number of patients, no statistically significant data could be derived.Conclusion
PVT is difficult to diagnose, with significant consequences. The presenting symptoms are nonspecific, and a high index of suspicion needs to be maintained. Cross-sectional imaging with computed tomography of the abdomen is recommended. Patients with PVT post-LSG without previous risk factors can be anticoagulated for 3 to 6 months with an international normalized ratio of 2 to 3. 相似文献54.
Telem Dana A. Jones Daniel B. Schauer Philip R. Brethauer Stacy A. Rosenthal Raul J. Provost David Jones Stephanie B. 《Surgical endoscopy》2018,32(10):4158-4164
Surgical Endoscopy - During the 2004 annual meeting of the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES), a panel of experts convened to provide updated information on best... 相似文献
55.
Dipak B. Ramkumar Niveditta Ramkumar Stephanie J. Tapp Wayne E. Moschetti 《The Journal of arthroplasty》2018,33(7):2092-2099.e9
Background
Total knee and hip arthroplasties can be associated with substantial blood loss, affecting morbidity and even mortality. Two pharmacological antifibrinolytics, ε-aminocaproic acid (EACA) and tranexamic acid (TXA) have been used to minimize perioperative blood loss, but both have associated morbidity. Given the added cost of these medications and the risks associated with then, a cost-effectiveness analysis was undertaken to ascertain the best strategy.Methods
A cost-effectiveness model was constructed using the payoffs of cost (in United States dollars) and effectiveness (quality-adjusted life expectancy, in days). The medical literature was used to ascertain various complications, their probabilities, utility values, and direct medical costs associated with various health states. A time horizon of 10 years and a willingness to pay threshold of $100,000 was used.Results
The total cost and effectiveness (quality-adjusted life expectancy, in days) was $459.77, $951.22, and $1174.87 and 3411.19, 3248.02, and 3342.69 for TXA, no pharmacologic hemostatic agent, and EACA, respectively. Because TXA is less expensive and more effective than the competing alternatives, it was the favored strategy. One-way sensitivity analyses for probability of transfusion and myocardial infarction for all 3 strategies revealed that TXA remains the dominant strategy across all clinically plausible values.Conclusion
TXA, when compared with no pharmacologic hemostatic agent and with EACA, is the most cost-effective strategy to minimize intraoperative blood loss in hip and knee total joint arthroplasties. These findings are robust to sensitivity analyses using clinically plausible probabilities. 相似文献56.
57.
58.
59.
Stephanie L. Wetzel Stanley Kerpel Renee F. Reich Paul D. Freedman 《Head and neck pathology》2015,9(2):269-272
Malignant rhabdoid tumors (MRTs) are exceedingly rare lesions. To our knowledge, only 2 cases have been reported in the oral cavity, with both examples occurring in infants. The current case is the third reported case of MRT of the oral cavity and the first reported case to occur in an adult at this location. The following report describes the clinical, histologic and immunohistochemical features of this tumor. 相似文献
60.